

4 SP42843

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number  
**WO 03/086380 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/22**,  
31/365, 31/40, 31/404, A61P 19/02, 37/00

(74) Agent: **THE PATENT CORPORATE BODY ARUGA  
PATENT OFFICE**; KYODO BLDG., 3-6, NIHON-  
BASHININGYOCHO 1-CHOME, CHUO-KU, Tokyo  
103-0013 (JP).

(21) International Application Number: PCT/JP03/04603

(22) International Filing Date: 11 April 2003 (11.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/372,114 15 April 2002 (15.04.2002) US  
10/196,428 17 July 2002 (17.07.2002) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants: **KOWA CO., LTD.** [JP/JP]; 6-29, NISHIKI 3-CHOME, NAKA-KU, NAGOYA-SHI, Aichi 460-8625 (JP). **NISSAN CHEMICAL INDUSTRIES, LTD.** [JP/JP]; 7-1, KANDA-NISHIKI-CHO 3-CHOME, CHIY-ODA-KU, Tokyo 101-0054 (JP).


(72) Inventors: **MORIKAWA, Shigeru**; 3-42-12-504, TAKADA, TOSHIMA-KU, Tokyo 171-0033 (JP). **IZUMI, Akashi**; 6-8-4-305, TSURUKAWA, MACHIDA-SHI, Tokyo 195-0061 (JP). **HAMAKUBO, Takao**; 3-6-27, IWADOMINAMI, KOMAE-SHI, Tokyo 201-0005 (JP). **KODAMA, Tatsuhiko**; 4-16-5, SHIMOUMA, SETA-GAYA-KU, Tokyo 154-0002 (JP).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PTX3 GENE EXPRESSION SUPPRESSING METHOD



or -CH=CH-, and R<sub>2</sub> represents a hydrogen atom or an alkyl group, or a lactone derivative thereof, or a salt thereof. According to the present invention, a PTX3 gene expression suppressor useful for the treatment of autoimmune diseases, especially rheumatoid arthritis can be provided.

(57) Abstract: A PTX3 gene expression suppressor comprising a compound represented by the following formula (1):  
$$\text{R}^1\text{-X-CH-CH}_2\text{-CH-CH}_2\text{-COOR}^2 \quad (1)$$
wherein R<sub>1</sub> represents an organic group, X represents -CH<sub>2</sub>CH<sub>2</sub>-

**DESCRIPTION****PTX3 GENE EXPRESSION SUPPRESSING METHOD****5      Technical Field**

This invention relates to a pentraxin 3 (PTX3) gene expression suppressor useful for the treatment of autoimmune diseases, especially rheumatoid arthritis.

**10     Background Art**

PTX3 gene was found as a novel gene the expression of which is induced by interleukin-1 (IL-1) from normal human umbilical vein endothelial cells (HUVEC) [Breviario et al.: J. Biol. Chem., 267(31), 22190-7 (1992)]. Further, a gene  
**15** (TSG-14 gene) the expression of which is induced by tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) from human fibroblasts was also found [Lee et al.: J. Immunol., 150(5), 1804-12 (1993)], and from a structural analysis, this gene has been found to be the same as PTX3 gene. PTX3 protein, in view of its molecular structure,  
**20** belongs to the so-called pentraxin family such as C-reactive protein (CRP) and serum amyloid P component (SAP), but its physiological functions are not known much. For reasons such that PTX3 protein is not induced by IL-6 and is different from the species of cells to be produced, PTX3 protein was suggested  
**25** to have functions different from CRP or SAP [J. Biol. Chem.,

267(31), 22190-7 (1992); Domyaku Koka (Arteriosclerosis),  
24(7-8), 375-80 (1996)].

As relevancy to the inflammatory reaction such as a  
formation of an arteriosclerotic layer or an ischemic heart  
5 disease, it has been found that the blood level of PTX3 is  
high in acute myocardial infarction patients [Circulation,  
102, 636-41 (2000)] and that expression of a tissue factor,  
an important factor for the formation of thrombus, is increased  
by PTX3 [Arterioscler. Thromb. Vasc. Biol., 22, 782-7 (2002)].

10 Recently, it has also been revealed that PTX3 gene is  
constantly expressed in synovial cells of a rheumatoid  
arthritis patient and that this expression is suppressed by  
inteferon- $\gamma$  (IFN- $\gamma$ ) or transforming growth factor- $\beta$  (TGF- $\beta$ )  
[Clin. Exp. Immunol., 119(1), 196-202 (2000)]. Moreover,  
15 PTX3 also takes part in a disorder via a complement pathway  
in an autoimmune disease, especially rheumatoid arthritis,  
because it binds to Clq, one of complement components, to  
activate the complement pathway [J. Biol. Chem., 272(52),  
32817-23 (1997)].

20 Suppression of PTX3 gene expression, therefore,  
suppresses worsening of an autoimmune disease, especially  
rheumatoid arthritis and further, results in its treatment.  
Except for IFN- $\gamma$  and TGF- $\beta$ , however, absolutely no substance  
has been known to date to suppress expression of PTX3 gene.


25 An object of the present invention is, therefore, to

provide a PTX3 gene expression suppressor, which suppresses expression of PTX3 gene and is effective for the treatment of an autoimmune disease, especially rheumatoid arthritis.

## 5 Disclosure of the Invention

Using a cultured human cell system, the present inventors have hence looked for substances which affect expression of PTX3 gene. As a result, it has been quite unexpectedly found that compounds represented by the below-described general  
10 formula (1) and their lactone derivatives and salts of these compounds and lactone derivatives, all of which are known as HMG-CoA reductase suppressors, especially pitavastatin calcium and atorvastatin calcium have activities to suppress expression of PTX3 gene, leading to the completion of the  
15 present invention.

Described specifically, the present invention provides a PTX3 gene expression suppressor comprising a compound represented by the following formula (1):



wherein  $\text{R}^1$  represents an organic group, X represents  $-\text{CH}_2\text{CH}_2-$  or  $-\text{CH}=\text{CH}-$ , and  $\text{R}^2$  represents a hydrogen atom or an alkyl group, or a lactone derivative thereof, or a salt thereof, as an active  
25 ingredient.

The present invention also provides a composition for suppressing expression of PTX3 gene comprising the compound represented by the above formula (1), or a lactone derivative thereof, or a salt thereof, and a pharmaceutically acceptable carrier.

The present invention also provides use, for producing PTX3 gene expression suppressor, of the compound represented by the above formula (1), or a lactone derivative thereof, or a salt thereof.

#### Brief Description of the Drawings

FIG. 1 is a diagram showing expression levels of PTX3 gene; and

FIG. 2 is a diagram electrophoretically illustrating suppression of gene expression.

#### Best Modes for Carrying Out the Invention

Compounds represented by the formula (1), their lactone derivatives and salts of these compounds and lactone derivatives, all of which are usable in the present invention, are known as HMG-CoA reductase suppressors useful as hyperlipidemia therapeutics. However, absolutely nothing is known as to whether or not they affect expression of PTX3 gene.

The organic group represented by  $R^1$  in the compound represented by the formula (1) may preferably be a substituted

or unsubstituted organic group having a cyclic structure.

Examples of the organic group having the cyclic structure can include indolyl, indenyl, pyridyl, pyrrolopyridyl, pyrazolopyridyl, thienopyridyl, pyrimidyl, pyrazolyl, pyrrolyl, imidazolyl, indolidyl, quinolyl, naphthyl, hexahydronaphthyl, cyclohexyl, phenylsilylphenyl, phenylthienyl and phenylfuryl groups, with hexahydronaphthyl, indolyl, pyridyl, pyrimidyl, pyrrolyl and quinolyl groups being particularly preferred.

Examples of substituent groups, which may substitute on these organic groups having the cyclic structures, can include hydroxyl group, linear, branched or cyclic alkyl groups, alkyloxyalkyl groups, alkylcarbonyloxy groups, alkyl-substituted amino groups, substituted alkylsulfonylamino groups, substituted phenylsulfonylamino groups, carbamoyl group which may be substituted by one or two alkyl or phenyl groups, halophenyl groups, alkylphenyl groups, alkoxyphenyl groups, phenyl group, and oxo group.

Among these substituents which may substitute on these organic groups having the cyclic structures, preferred are linear, branched or cyclic  $C_{1-6}$  alkyl groups,  $C_{2-7}$  alkyloxyalkyl groups,  $C_{1-4}$  acyloxy groups,  $C_{1-4}$  alkyl-substituted amino groups,  $C_{1-4}$  alkyl-substituted  $C_{1-4}$  alkylsulfonylamino groups,  $C_{1-4}$  alkyl-substituted phenylsulfonylamino groups,  $C_{1-4}$  alkyl-substituted carbamoyl groups, phenyl-substituted

carbamoyl groups, fluorophenyl groups, bromophenyl groups, iodophenyl groups, methylphenyl groups, ethylphenyl groups, methoxyphenyl groups, ethoxyphenyl groups and phenyl group, with isopropyl, cyclopropyl and p-fluorophenyl groups being particularly preferred.

Examples of the alkyl group represented by  $R^2$  may include a linear, branched or cyclic alkyl group having 1-6 carbon atoms.

The lactone derivative can be obtained by subjecting its corresponding compound, which is represented by the formula (1), to lactonization in a manner known per se in the art, for example, under acidic conditions.

The salts of the compound represented by the formula (1) and its lactone derivative are physiologically acceptable salts. Examples can include alkali metal salts such as the sodium salts and potassium salts, alkaline earth metal salts such as the calcium salts and magnesium salts, organic amine salts such as the phenethylamine salts, and the ammonium salts, with the sodium salts and calcium salts being more preferred.

These compounds are disclosed, for example, in US-A-4,739,073 and EP-A-114,027; EP-A-367,895; US-A-5,001,255, US-A-4,613,610, US-A-4,851,427, US-A-4,755,606, US-A-4,808,607, US-A-4,751,235, US-A-4,939,159, US-A-4,822,799, US-A-4,804,679, US-A-4,876,280, US-A-4,829,081, US-A-4,927,851,

US-A-4,588,715; F.G. Kathawala, Medical Research Reviews, 11, 121-146 (1991), EP-A-304,063; EP-A-330,057; US-A-5,026,708, US-A-4,868,185; EP-A-324,347; EP-A-300,278; US-A-5,013,749, US-A-5,872,130, US-A-5,856,336, US-A-4,231,938, 5 US-A-4,444,784, US-A-4,346,227, US-A-5,354,772, US-A-5,273,995, US-A-5,177,080, US-A-3,983,140, JP-B-2,648,897, US-A-5,260,440, Bioorganic & Medicinal Chemistry, 5, 437 (1977), JP-B-2,569,746, EP-B-304,063, and US-A-5,856,336.

10 Preferred examples of the active ingredient in the method according to the present invention for the suppression of expression of PTX3 gene can include lovastatin

(US-A-4,231,938:

(+)-(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl 15 -8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthyl (S)-2-methylbutyrate), simvastatin

(US-A-4,444,784:

(+)-(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl -8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]e 20 thyl]-1-naphthyl 2,2-dimethylbutanoate), pravastatin

(US-A-4,346,227:

(+)-(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy- 2-methyl-8-[(S)-2-methylbutyryloxy]-1,2,6,7,8,8a-hexahydr o-1-naphthyl]heptanoic acid), fluvastatin (US-A-5,354,772:

25 (3RS,5SR,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-i



ndol-2-yl]-3,5-dihydroxy-6-heptenoic acid), atorvastatin  
(US-A-5,273,995:

(3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamonyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid),

5 cerivastatin (US-A-5,177,080:

(3R,5S)-erythro-(E)-7-[4-(4-fluorophenyl)-2,6-diisopropyl-5-methoxymethyl-pyridin-3-yl]-3,5-dihydroxy-6-heptenoic acid), mevastatin (US-A-3,983,140:

(+)-(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-7-methyl-8-[  
10 2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthyl(S)-2-methylbutyrate), rosuvastatin

(US-A-5,260,440, JP-B-2,648,897:

7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonfylaminopyrimidin)-5-yl]-(3R,5S)-dihydroxy-(E)-6-heptenoic acid), and pitavastatin (US-A-5,856,336,

15 JP-B-2,569,746:

(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid, and their salts. In

particular, pitavastatin and its salts and atorvastatin and  
20 its salts are preferred.

The compound represented by the formula (1) and its lactone derivative and the salts of these compound and lactone derivatives, all of which are useful in the present invention, significantly suppress expression of mRNA for PTX3 in human  
25 cells and therefore, are useful in the PTX3 gene expression

suppressor according to the present invention, especially for the treatment of autoimmune diseases such as rheumatoid arthritis. Further, they also permit *inter alia* development of experiment systems, in which PTX3 takes part, and screening  
5 of novel medicines.

Illustrative administration routes for the compound (1) or its lactone or the salt of the compound or lactone can include oral administrations by tablets, capsules, a granule, a powder, a syrup and the like; and parenteral administrations by an  
10 intravenous injection, an intramuscular injection, suppositories, an inhalant, a transdermal preparation, an eye drop, a nasal drop and the like.

To formulate medicinal preparations in such various forms as described above, the active ingredient can be used  
15 either singly or in combination with one or more of pharmaceutically acceptable excipients, binders, extenders, disintegrants, surfactants, lubricants, dispersants, buffering agents, preservatives, corrigents, perfumes, coating materials, carriers, diluents and the like, as needed.

20 Of these administration routes, oral administrations are preferred. Upon formulation of a medicinal preparation for oral administration, it is preferred to adjust the pH in view of the stability of the active ingredient (JP-A-2-0006406, JP-B-2,774,037, WO-A-97/23200, etc.).

25 The dosage of the active ingredient varies *inter alia*

depending on the weight, age, sex and conditions of each patient. In the case of an adult, however, it is generally preferred to orally or parenterally administer the active ingredient at a daily dosage of from 0.01 to 1,000 mg, specifically from 0.1 to 100 mg in terms of the compound represented by formula (1) at once or in several portions.

### Examples

The present invention will hereinafter be described in detail based on Examples. It should however be borne in mind that the present invention is not limited to the following Examples.

#### Example 1

Two days after inoculation of normal human umbilical vein endothelial cells (HUVEC) or human coronary artery smooth muscle cells (HCASMC) at  $3 \times 10^5$  cells/10 cm dish, pitavastatin calcium or atorvastatin calcium was added to 1.1  $\mu\text{mol/L}$  and 6.6  $\mu\text{mol/L}$ , respectively. Dimethyl sulfoxide, a solvent for both of the active ingredients, was added to a control (final concentration: 0.0066 v/v%). Eight hours after the addition, total RNA was extracted with "ISOGEN" (trade mark, product of NIPPON GENE CO., LTD.). The following procedures were conducted in accordance with the procedures manual of Affymetrix, Inc. Described specifically, mRNA was isolated from the above-obtained total RNA, and based on the mRNA, cDNA

was synthesized. Further, biotin-labeled cRNA was synthesized by *in vitro* transcription. Subsequent to purification, the biotin-labeled cRNA was subjected to fragmentation by heat treatment to prepare fragmented cRNA for use in a gene expression analysis.

Gene expression analysis method: The fragmented cRNA was poured into "Hugene Human FL Array" (trade name, product of Affymetrix, Inc.), and hybridization was conducted at 45°C for 16 hours. Subsequent to washing, staining with phycoerythrin-labeled streptavidin and biotinylated antistreptavidin antibody was applied, and gene expression information was inputted by "GeneChip™ Scanner" (trade name, manufactured by Hewlett Packard Company). The information was analyzed by "GENECHIP SOFTWARE" (trade name, product of Affymetrix, Inc.) to compare expression levels.

The results of the measurement are shown in FIG. 1.

The expression of PTX3 gene in HUVEC upon elapsed time of 8 hours after the addition of the active ingredient was significantly suppressed to 32.7 and 39.2 in the pitavastatin calcium and atorvastatin calcium addition groups, respectively, as opposed to 1113.0 in the control. The expression of PTX3 gene in HCASMC upon elapsed time of 8 hours after the addition of the active ingredient was also significantly suppressed to 452.5 and 432.1 in the pitavastatin calcium and atorvastatin calcium addition groups,

respectively, as opposed to 1028.3 in the control.

#### Example 2

Two days after inoculation of HUVEC at  $3 \times 10^5$  cells/10 cm dish, pitavastatin calcium or atorvastatin calcium was added to 1.1  $\mu\text{mol/L}$  and 6.6  $\mu\text{mol/L}$ , respectively. To ascertain possible concentration dependency of PTX3 gene expression suppressing effect of pitavastatin, pitavastatin calcium was also added to 1  $\mu\text{mol/L}$  and 10  $\mu\text{mol/L}$  upon elapsed time of 2 days after inoculation of HUVEC or HCASMC at  $3 \times 10^5$  cells/10 cm dish. To controls under the respective conditions, dimethyl sulfoxide, a solvent for both of the active ingredients, was added (final concentration: 0.0066 v/v%). Eight or 24 hours after the addition, total RNA was extracted with "ISOGEN" (trade mark, product of NIPPON GENE CO., LTD.). The total RNA was subjected to RT-PCR in a manner known per se in the art, and amplified DNA fragments were subjected to agarose gel electrophoresis to compare expression levels.

Reaction conditions and the like for PT-PCR:

PT reaction: Conducted using "RNA PCR Core Kit" (trade name, product of Roche Molecular Systems, Inc.).

PCR: Using "Expanded<sup>TM</sup> High Fidelity PCR System" (trade name, manufactured of Boehringer Mannheim AG), thermal cycling was conducted through 25 cycles according to the following schemes: 95°C for 1 minute - 57°C for 1 minute - 72°C for 1 minute.

Incidentally, as PCR primers, the followings were used in sets: SEQ ID No:1 (Forward) and SEQ ID No: 2 (Reverse) in the case of PTX3; base SEQ ID No:3 (Forward) and SEQ ID No: 4 (Reverse) in the case of GAPDH.

The results are shown in FIG. 2.

The expression of PTX3 gene in HUVEC was suppressed by the addition of pitavastatin calcium or atorvastatin calcium both 8 hours later and 24 hours later compared with the control.


Further, the expressions of PTX3 gene in HUVEC and HCASMC were concentration-dependently suppressed by the addition of pitavastatin calcium both 8 hours later and 24 hours later.

#### **Industrial Applicability**

The present invention can provide a PTX3 gene expression suppressor useful for the treatment of autoimmune diseases, especially rheumatoid arthritis.

## CLAIMS

1. A PTX3 gene expression suppressor comprising a compound represented by the following formula (1):



wherein R<sup>1</sup> represents an organic group, X represents -CH<sub>2</sub>CH<sub>2</sub>- or -CH=CH-, and R<sup>2</sup> represents a hydrogen atom or an alkyl group, or a lactone derivative thereof, or a salt thereof, as an active ingredient.

10

2. The suppressor according to claim 1, wherein R<sup>1</sup> is a substituted or unsubstituted indolyl, indenyl, pyridyl, pyrrolopyridyl, pyrazolopyridyl, thienopyridyl, pyrimidyl, pyrazolyl, pyrrolyl, imidazolyl, indolidyl, quinolyl, naphthyl, hexahydronaphthyl, cyclohexyl, phenylsilylphenyl, phenylthienyl or phenylfuryl group.

15

3. The suppressor according to claim 1, wherein said active ingredient is lovastatin, pravastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, rosuvastatin, mevastatin or pitavastatin, or a salt thereof.


20

4. The suppressor according to claim 1, wherein said active ingredient is pitavastatin or salt thereof.

5. The suppressor according to claim 1, wherein said active ingredient is atorvastatin or salt thereof.

25 6. A medicine for treating an autoimmune disease comprising a compound represented by the following formula

(1):



5 wherein R<sup>1</sup> represents an organic group, X represents -CH<sub>2</sub>CH<sub>2</sub>- or -CH=CH-, and R<sup>2</sup> represents a hydrogen atom or an alkyl group, or a lactone derivative thereof, or a salt thereof, as an active ingredient.

10 7. The medicine according to claim 6, wherein R<sup>1</sup> is a substituted or unsubstituted indolyl, indenyl, pyridyl, pyrrolopyridyl, pyrazolopyridyl, thienopyridyl, pyrimidyl, pyrazolyl, pyrrolyl, imidazolyl, indolidyl, quinolyl, naphthyl, hexahydronaphthyl, cyclohexyl, phenylsilylphenyl, phenylthienyl or phenylfuryl group.

15 8. The medicine according to claim 6, wherein said active ingredient is lovastatin, pravastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, rosuvastatin, mevastatin or pitavastatin, or a salt thereof.


20 9. The medicine according to claim 6, wherein said active ingredient is pitavastatin or salt thereof.

10. The medicine according to claim 6, wherein said active ingredient is atorvastatin or salt thereof.

11. A medicine for treating rheumatoid arthritis comprising a compound represented by the following formula

25 (1):





wherein  $\text{R}^1$  represents an organic group, X represents  $-\text{CH}_2\text{CH}_2-$   
 5 or  $-\text{CH}=\text{CH}-$ , and  $\text{R}^2$  represents a hydrogen atom or an alkyl group,  
 or a lactone derivative thereof, or a salt thereof, as an active  
 ingredient.


12. The medicine according to claim 11, wherein  $\text{R}^1$  is  
 a substituted or unsubstituted indolyl, indenyl, pyridyl,  
 10 pyrrolopyridyl, pyrazolopyridyl, thienopyridyl, pyrimidyl,  
 pyrazolyl, pyrrolyl, imidazolyl, indolidyl, quinolyl,  
 naphthyl, hexahydronaphthyl, cyclohexyl, phenylsilylphenyl,  
 phenylthienyl or phenylfuryl group.

13. The medicine according to claim 11, wherein said  
 15 active ingredient is lovastatin, pravastatin, simvastatin,  
 fluvastatin, cerivastatin, atorvastatin, rosuvastatin,  
 mevastatin or pitavastatin, or a salt thereof.

14. The medicine according to claim 11, wherein said  
 active ingredient is pitavastatin or salt thereof.

20 15. The medicine according to claim 11, wherein said  
 active ingredient is atorvastatin or salt thereof.

16. A composition for suppressing expression of PTX3  
 gene comprising a compound represented by the following formula  
 (1):



wherein  $R^1$  represents an organic group, X represents  $-\text{CH}_2\text{CH}_2-$  or  $-\text{CH}=\text{CH}-$ , and  $R^2$  represents a hydrogen atom or an alkyl group, or a lactone derivative thereof, or a salt thereof, and a pharmaceutically acceptable carrier.


5           17. The composition according to claim 16, wherein  $R^1$  is a substituted or unsubstituted indolyl, indenyl, pyridyl, pyrrolopyridyl, pyrazolopyridyl, thienopyridyl, pyrimidyl, pyrazolyl, pyrrolyl, imidazolyl, indolidyl, quinolyl, naphthyl, hexahydronaphthyl, cyclohexyl, phenylsilylphenyl,  
10 phenylthienyl or phenylfuryl group.

18. The composition according to claim 16, wherein said active ingredient is lovastatin, pravastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, rosuvastatin, mevastatin or pitavastatin, or a salt thereof.

15           19. The composition according to claim 16, wherein said active ingredient is pitavastatin or salt thereof.

20. The composition according to claim 16, wherein said active ingredient is atorvastatin or salt thereof.

21. A composition for treating an autoimmune disease  
20 comprising a compound represented by the following formula (1):



25           wherein  $R^1$  represents an organic group, X represents  $-\text{CH}_2\text{CH}_2-$  or  $-\text{CH}=\text{CH}-$ , and  $R^2$  represents a hydrogen atom or an alkyl group,

or a lactone derivative thereof, or a salt thereof, and a pharmaceutically acceptable carrier.


22. The composition according to claim 21, wherein R<sup>1</sup> is a substituted or unsubstituted indolyl, indenyl, pyridyl, pyrrolopyridyl, pyrazolopyridyl, thienopyridyl, pyrimidyl, 5 pyrazolyl, pyrrolyl, imidazolyl, indolidyl, quinolyl, naphthyl, hexahydronaphthyl, cyclohexyl, phenylsilylphenyl, phenylthienyl or phenylfuryl group.

23. The composition according to claim 21, wherein said 10 active ingredient is lovastatin, pravastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, rosuvastatin, mevastatin or pitavastatin, or a salt thereof.

24. The composition according to claim 21, wherein said active ingredient is pitavastatin or salt thereof.

15 25. The composition according to claim 21, wherein said active ingredient is atorvastatin or salt thereof.

26. A composition for treating rheumatoid arthritis comprising a compound represented by the following formula (1):



wherein R<sup>1</sup> represents an organic group, X represents -CH<sub>2</sub>CH<sub>2</sub>- or -CH=CH-, and R<sup>2</sup> represents a hydrogen atom or an alkyl group, 25 or a lactone derivative thereof, or a salt thereof, and a pharmaceutically carrier.


27. The composition according to claim 26, wherein R<sup>1</sup> is a substituted or unsubstituted indolyl, indenyl, pyridyl, pyrrolopyridyl, pyrazolopyridyl, thienopyridyl, pyrimidyl, pyrazolyl, pyrrolyl, imidazolyl, indolidyl, quinolyl, naphthyl, hexahydronaphthyl, cyclohexyl, phenylsilylphenyl, phenylthienyl or phenylfuryl group.

28. The composition according to claim 26, wherein said active ingredient is lovastatin, pravastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, rosuvastatin, mevastatin or pitavastatin, or a salt thereof.

29. The composition according to claim 26, wherein said active ingredient is atorvastatin or a salt thereof.

30. The composition according to claim 26, wherein said active ingredient is pitavastatin or salt thereof.

31. Use, for producing PTX3 gene expressing suppressor, of a compound represented by the following formula (1):



wherein R<sup>1</sup> represents an organic group, X represents -CH<sub>2</sub>CH<sub>2</sub>- or -CH=CH-, and R<sup>2</sup> represents a hydrogen atom or an alkyl group, or a lactone derivative thereof, or a salt thereof.

32. The use according to claim 31, wherein R<sup>1</sup> is a substituted or unsubstituted indolyl, indenyl, pyridyl, pyrrolopyridyl, pyrazolopyridyl, thienopyridyl, pyrimidyl, pyrazolyl, pyrrolyl, imidazolyl, indolidyl, quinolyl,


naphthyl, hexahydronaphthyl, cyclohexyl, phenylsilylphenyl, phenylthienyl or phenylfuryl group.

33. The use according to claim 31, wherein said active ingredient is lovastatin, pravastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, rosuvastatin, mevastatin or pitavastatin, or a salt thereof.

34. The use according to claim 31, wherein said active ingredient is pitavastatin or salt thereof.

35. The use according to claim 31, wherein said active ingredient is atorvastatin or salt thereof.

36. Use, for producing a medicine for treating an autoimmune disease, of a compound represented by the following formula (1):



wherein  $\text{R}^1$  represents an organic group, X represents  $-\text{CH}_2\text{CH}_2-$  or  $-\text{CH}=\text{CH}-$ , and  $\text{R}^2$  represents a hydrogen atom or an alkyl group, or a lactone derivative thereof, or a salt thereof, as an active ingredient.


37. The use according to claim 36, wherein  $\text{R}^1$  is a substituted or unsubstituted indolyl, indenyl, pyridyl, pyrrolopyridyl, pyrazolopyridyl, thienopyridyl, pyrimidyl, pyrazolyl, pyrrolyl, imidazolyl, indolidyl, quinolyl, naphthyl, hexahydronaphthyl, cyclohexyl, phenylsilylphenyl, phenylthienyl or phenylfuryl group.

38. The use according to claim 36, wherein said active ingredient is lovastatin, pravastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, rosuvastatin, mevastatin or pitavastatin, or a salt thereof.

5 39. The use according to claim 36, wherein said active ingredient is pitavastatin or salt thereof.

40. The use according to claim 36, wherein said active ingredient is atorvastatin or salt thereof.

41. Use, for producing a medicine for treating  
10 rheumatoid arthritis, of a compound represented by the following formula (1):



15 wherein R<sup>1</sup> represents an organic group, X represents -CH<sub>2</sub>CH<sub>2</sub>- or -CH=CH-, and R<sup>2</sup> represents a hydrogen atom or an alkyl group, or a lactone derivative thereof, or a salt thereof.

42. The use according to claim 41, wherein R<sup>1</sup> is a substituted or unsubstituted indolyl, indenyl, pyridyl,  
20 pyrrolopyridyl, pyrazolopyridyl, thienopyridyl, pyrimidyl, pyrazolyl, pyrrolyl, imidazolyl, indolidyl, quinolyl, naphthyl, hexahydronaphthyl, cyclohexyl, phenylsilylphenyl, phenylthienyl or phenylfuryl group.


43. The use according to claim 41, wherein said active  
25 ingredient is lovastatin, pravastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, rosuvastatin,

mevastatin or pitavastatin, or a salt thereof.

44. The use according to claim 41, wherein said active ingredient is pitavastatin or salt thereof.

45. The use according to claim 41, wherein said active ingredient is atorvastatin or salt thereof.

46. A method for suppressing expression of PTX3 gene, which comprises administering an effective amount of a compound, which is represented by the following formula (1):



wherein R<sup>1</sup> represents an organic group, X represents -CH<sub>2</sub>CH<sub>2</sub>- or -CH=CH-, and R<sup>2</sup> represents a hydrogen atom or an alkyl group, or a lactone derivative thereof, or a salt thereof, as an active ingredient.

47. The method according to claim 46, wherein R<sup>1</sup> is a substituted or unsubstituted indolyl, indenyl, pyridyl, pyrrolopyridyl, pyrazolopyridyl, thienopyridyl, pyrimidyl, pyrazolyl, pyrrolyl, imidazolyl, indolidyl, quinolyl, naphthyl, hexahydronaphthyl, cyclohexyl, phenylsilylphenyl, phenylthienyl or phenylfuryl group.


48. The method according to claim 46, wherein said active ingredient is lovastatin, pravastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, rosuvastatin, mevastatin or pitavastatin, or a salt thereof.

49. The method according to claim 46, wherein said

active ingredient is pitavastatin or salt thereof.

50. The method according to claim 46, wherein said active ingredient is atorvastatin or salt thereof.

51. The method for treating an autoimmune disease,  
5 which comprises administering an effective amount of a compound,  
which is represented by the following formula (1):



10 wherein R<sup>1</sup> represents an organic group, X represents -CH<sub>2</sub>CH<sub>2</sub>-  
or -CH=CH-, and R<sup>2</sup> represents a hydrogen atom or an alkyl group,  
or a lactone derivative thereof, or a salt thereof, as an active  
ingredient.

52. The method according to claim 51, wherein R<sup>1</sup> is  
15 a substituted or unsubstituted indolyl, indenyl, pyridyl,  
pyrrolopyridyl, pyrazolopyridyl, thienopyridyl, pyrimidyl,  
pyrazolyl, pyrrolyl, imidazolyl, indolidyl, quinolyl,  
naphthyl, hexahydronaphthyl, cyclohexyl, phenylsilylphenyl,  
phenylthienyl or phenylfuryl group.

20 53. The method according to claim 51, wherein said  
active ingredient is lovastatin, pravastatin, simvastatin,  
fluvastatin, cerivastatin, atorvastatin, rosuvastatin,  
mevastatin or pitavastatin, or a salt thereof.


54. The method according to claim 51, wherein said active  
25 ingredient is pitavastatin or salt thereof.

55. The method according to claim 51, wherein said active



ingredient is atorvastatin or salt thereof.

56. A method for treating rheumatoid arthritis, which comprises administering an effective amount of a compound, which is represented by the following formula (1):



wherein R<sup>1</sup> represents an organic group, X represents -CH<sub>2</sub>CH<sub>2</sub>- or -CH=CH-, and R<sup>2</sup> represents a hydrogen atom or an alkyl group, or a lactone derivative thereof, or a salt thereof, as an active ingredient.

57. The method according to claim 56, wherein R<sup>1</sup> is a substituted or unsubstituted indolyl, indenyl, pyridyl, pyrrolopyridyl, pyrazolopyridyl, thienopyridyl, pyrimidyl, pyrazolyl, pyrrolyl, imidazolyl, indolidyl, quinolyl, naphthyl, hexahydronaphthyl, cyclohexyl, phenylsilylphenyl, phenylthienyl or phenylfuryl group.

58. The method according to claim 56, wherein said active ingredient is lovastatin, pravastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, rosuvastatin, mevastatin or pitavastatin, or a salt thereof.

59. The method according to claim 56, wherein said active ingredient is pitavastatin or salt thereof.

60. The method according to claim 56, wherein said active ingredient is atorvastatin or salt thereof.





Fig 2



PI: Pitavastatin calcium,      AT: Atorvastatin calcium

## SEQUENCE LISTING

&lt;110&gt; KOWA CO., LTD.

&lt;120&gt; PTX3 GENE EXPRESSION SUPPRESSING METHOD

&lt;130&gt; KW0101

5

&lt;140&gt;

&lt;141&gt;

&lt;150&gt; US 60/372,114

10

&lt;151&gt; 2002-04-15

&lt;150&gt; US 10/196,428

&lt;151&gt; 2002-07-17

15

&lt;160&gt; 4

&lt;210&gt; 1

&lt;211&gt; 21

&lt;212&gt; DNA

20

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Designed primer PTX3  
(forward)

25

&lt;400&gt; 1

agtgtttgtg gtgggtggag a

21

<210> 2

<211> 21

5 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Designed primer PTX3  
(Reverse)

10

<400> 2

ttatgaaaca tactgagctc c

21

<210> 3

15 <211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Designed primer  
20 GAPDH (forward)

<400> 3

acaacttttg tatcgtggaa gga

23

25 <210> 4

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

5 <223> Description of Artificial Sequence: Designed primer  
GAPDH (Reverse)

<400> 4

ccgttcagct cagggatgac ct

22

10

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 03/04603

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7 A61K31/22 A61K31/365 A61K31/40 A61K31/404 A61P19/02 A61P37/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, MEDLINE, BIOSIS, WPI Data, PAJ, CHEM ABS Data		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02 24194 A (MACH FRANCOIS ;NOVIMMUNE S A (CH)) 28 March 2002 (2002-03-28) claims 1-93	1-60
A	WO 99 26657 A (UNIV SOUTH CAROLINA ;SINGH INDERJIT (US)) 3 June 1999 (1999-06-03)	
A	WO 00 53566 A (TILLYER RICHARD D ;REIDER PAUL J (US); XU FENG (US); MERCK & CO IN) 14 September 2000 (2000-09-14)	
<input type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
<b>* Special categories of cited documents :</b> *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family		
Date of the actual completion of the international search  20 August 2003		Date of mailing of the international search report  29/08/2003
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  Stienon, P

Form PCT/ISA/210 (second sheet) (July 1992)

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/JP 03/04603

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



INTERNATIONAL SEARCH REPORT

International Application No. PCT/JP 03 04603

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 50-60 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

-----

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 03/04603

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0224194	A	28-03-2002	AU 1052102 A	02-04-2002
			CA 2422820 A1	28-03-2002
			WO 0224194 A2	28-03-2002
			EP 1322306 A2	02-07-2003
			US 2002159973 A1	31-10-2002
			US 2002159974 A1	31-10-2002
			US 2002156122 A1	24-10-2002
WO 9926657	A	03-06-1999	WO 9926657 A1	03-06-1999
			US 6511800 B1	28-01-2003
WO 0053566	A	14-09-2000	AT 240934 T	15-06-2003
			AU 2637000 A	28-09-2000
			CA 2365869 A1	14-09-2000
			DE 60002769 D1	26-06-2003
			DK 1036783 T3	23-06-2003
			EP 1036783 A1	20-09-2000
			EP 1163203 A1	19-12-2001
			JP 2000281626 A	10-10-2000
			JP 2002539108 T	19-11-2002
			WO 0053566 A1	14-09-2000